Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

Posted:
14
December 2020

Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.

The development of the drug for patients with cardiovascular diseases, is an antisense oligonucleotide (ASO) inhibiting the non-coding microRNA-132 (miR132) that directly regulates adverse cardiac remodelling.

Richmond Pharmacology’s CEO, Jorg Taubel M.D. commented "We are pleased to be working alongside Cardior Pharmaceuticals to conduct the first-in-human studies for this pioneering treatment. The benefit of conducting the first in human study in the target population is great. The drug development time may be reduced, improving efficiencies, and potentially enabling patients to access the medication faster."

A summary of the study was published in the European Heart Journal

Cardior’s therapeutic approach is using distinctive ncRNA signatures driving the molecular reprogramming that causes maladaptive remodelling and heart failure. Drug candidates developed by Cardior represent first-in-class ncRNA therapeutics and diagnostics for patients with myocardial infarction and various forms of heart failure.

The study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic (PD) properties of CDR132L in patients with stable heart failure (HF) of ischemic origin (NYHA 1-3).

Richmond Pharmacology supported the German based biopharmaceutical company with the operation of the first-in-human stage of the study. This was the first trial of an ASO inhibiting a miRNA performed in heart failure patients. Since novel generation ASOs are widely considered as safe treatment due to the high target selectivity and a well-established PK, this first-in-human study was performed straight in heart failure patients, as advised in meetings with regulators, rather than healthy volunteers. In the trial, CDR132L met all endpoints and showed excellent tolerability and safety.

Claudia Ulbrich, CEO Of Cardior stated “We are very pleased with the outcome of our clinical study, the first-ever trial of an oligonucleotide-based drug in heart failure patients,” she continued “These encouraging results are an excellent basis for starting Phase II studies in subacute and chronic heart failure patients. The outcome of this trial also underlines the potential of RNA-based therapies as a causal approach to treat complex diseases.”

Richmond Pharmacology has demonstrable experience recruiting large cohorts of patients to Phase I, II and III trials. This reduces the need to run multi-centre studies providing significant savings in time and cost.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

What 20 years of clinical research has taught us about our industry and the future of drug development

June 9, 2021
As Richmond Pharmacology approaches its 20th anniversary our co-founder and CEO reflects on the developments, regulatory changes, and innovations within the life science industry in an article in the PharmaTimes.
Read more

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more